Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson
Annals of Clinical and Translational Neurology · Wiley · 2026-11-12 · DOI: 10.1002/acn3.70395

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles